14 results about "Serum amyloid P" patented technology

The present invention provides a kit for determining serum amyloid A, and its preparation and application. The kit of the present invention optimally screens the buffer systems, components and concentrations of inorganic salts in Reagent 1 and Reagent 2, particularly adds polyanions and DSS, and uses a quenching agent in the preparation process of anti-SAA antibody-coated latex particles. Through the optimal screening of these components, the prepared kit significantly improves the specific recognition and binding ability to serum amyloid A, and enhances performance indicators such as the sensitivity, linear range, anti-interference ability, stability and repeatability of the kit. Among them, in the linear range of 2 mg / L to 500 mg / L, the detected values have good linearity, accuracy and usability, thereby enhancing the comprehensive performance of the immunoassay of serum amyloid A.

The invention relates to the technical field of detection methods, in particular to a method for detecting serum amyloid protein A. The specific technical scheme is as follows: after a serum amyloid protein A secondary antibody donor bead complex and a serum amyloid protein A primary antibody receptor bead complex are mixed with an antigen to be detected, a light-emitting signal value is detected. The method for detecting the serum amyloid protein A disclosed by the invention has the advantages of wide detection limit, homogeneous phase, no washing, simplicity and convenience in operation, good specificity, good repeatability and good anti-interference performance, can be used for rapidly detecting infection markers, and has clinical application potential.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody combination capable of simultaneously recognizing equine and feline serum amyloid A (SAA) and its application. The monoclonal antibody combination comprises 6E10 and 5A6. The CDR sequences of the heavy and light chain variable regions of 6E10 are shown in SEQ ID NO. 1-6, and the CDR sequences of the heavy and light chain variable regions of 5A6 are shown in SEQ ID NO. 7-12. This antibody combination can highly specifically recognize and bind to recombinant equine and feline SAA proteins, achieving multiple uses with a single antibody and reducing raw material development and production costs. The colloidal gold test strip constructed based on this combination exhibits high specificity, high sensitivity, and a wide detection range, with no cross-reactivity. It is easy to operate and requires no complex instruments, providing a stable and reliable biorecognition tool for assessing and monitoring inflammation-related physiological states in animals.

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.

A serum amyloid protein A and C reactive protein joint detection kit comprises a kit body, a sliding rod, a movable seat, a lock sleeve, a positioning rod, a rotating sleeve, a main gear disc and a movable plate, the upper portion of the kit body is connected with a kit cover, the kit body is provided with a connecting block, the kit cover is provided with a connecting lug, the connecting lug is connected with the connecting block through a shaft rod, and the shaft rod is sequentially connected with the connecting lug and the connecting block. The kit is connected with the lock seat, the box cover is connected with the lock tongue, the lock tongue is matched with the lock seat, the lock tongue is connected with the lock seat, the upper part of the kit is provided with a fixing plate, the fixing plate is provided with a plurality of placing holes, the placing holes are matched with test tubes, the test tubes penetrate through the placing holes and are connected with the inner side of the rubber ring, and the outer side of the rubber ring is connected with the fixing plate.

The present disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.

The utility model provides a cat serum amyloid protein A detection sampler, and relates to the technical field of serum sampling, the cat serum amyloid protein A detection sampler is characterized in that the top end part of a suction tube is rotatably connected with a holding frame with a U-shaped structure, two spacer sleeves are symmetrically and slidably sleeved on two long side shafts of the holding frame, a top bolt is installed on each spacer sleeve in a penetrating and screwing manner, and the top bolt is fixedly connected with the suction tube; the head ends of the two top bolts correspondingly abut against and make contact with the two long side shafts of the maintaining frame, and the two long side shafts of the maintaining frame are each provided with a scale indicating the capacity. And a pushing driving part is slidably mounted on the retaining frame, two horizontal limiting plates are symmetrically fixed to the pushing driving part, and the head ends of the two horizontal limiting plates are correspondingly in sliding fit with the two long side shafts of the retaining frame. The holding frame is rotatably mounted, and when the telescopic inflator is pulled, inserted, disassembled, assembled and replaced, the holding frame can swing downwards to leave a space for a hand to pull and insert at the top end of the telescopic inflator, so that the telescopic inflator can be pulled, inserted, disassembled and assembled conveniently.

The utility model provides a cat serum amyloid protein A reserve kit, belongs to the technical field of in-vitro detection equipment, and aims to solve the problem that when an existing reserve kit is moved by a doctor, a reagent bottle is separated from a slot of the reserve kit, so that the use effect of the reserve kit is influenced. Comprising a kit main body, a taking handle, a supporting base, a protection driving shaft, a reagent placing groove, a test auxiliary mechanism and a taking protection mechanism, the supporting bases are fixedly connected to the lower end of the kit main body respectively; the protective driving shaft is rotationally connected to the lower end of the inner side of the kit main body; the reagent placing grooves are respectively formed in the upper part of the kit main body; the test auxiliary mechanism is arranged on the inner side of the kit main body; and the taking protection mechanisms are arranged on the inner side of the kit main body, so that the reagent bottles are clamped, the stability of the reagent bottles in the moving process of the whole kit main body is ensured, and the using effect of the whole kit main body is improved.

The invention relates to the technical field of biological medicine, in particular to a biomarker combination, a kit of the biomarker combination and application of the biomarker combination in diagnosis of acute Stanford B-type aortic dissection (ATBAD). The biomarker combination comprises serum amyloid protein A1 (SAA1), serum amyloid protein A2 (SAA2), C-reactive protein (CRP), neutrophil elastinase (ELANE), matrix metalloenzyme 9 (MMP9), nest protein 1 (NID1), mannose binding lectin 2 (LMAN2) and proprotein convertase subtilisin / kexin type 9 (PCSK9), and the biomarker combination can realize high-sensitivity and high-accuracy detection of ATBAD. And the anti-interference capability is excellent.

The invention relates to a serum amyloid A (SAA) protein mutant and a preparation method thereof. Specifically, the serum amyloid A protein mutant contains core amino acids selected from the following groups: (a) the first amino acid is A or G; (b) the fifth amino acid is A or G; and / or (c) the 8th amino acid is A; wherein the amino acid position number is based on the sequence represented by any one of SEQ ID NO: 1 and SEQ ID NO: 69 to SEQ ID NO: 73. According to the method, the yield of SAA protein is increased, the problem of endotoxin is avoided, and the difference of folding modes or immunogenicity when other systems are used for expressing protein is avoided.

The utility model relates to a serum amyloid protein A determination kit. The kit comprises a shell and a test strip, the test strip comprises a support plate, a sample pad, a combination pad, a reaction film and absorbent paper, the shell comprises an upper cover and a lower cover, and the upper cover is provided with a sample adding hole and an observation window; colloidal carbon marked by a first serum amyloid protein A monoclonal antibody is sprayed on the combination pad; the reaction film is provided with a detection line and a quality control line, the detection line is sprayed with a second serum amyloid protein A monoclonal antibody, and the quality control line is sprayed with a goat-anti-mouse second antibody; the sample pad, the combination pad, the reaction film and the absorbent paper are fixed on the surface of the support plate; the conjugate pad is overlapped with one end, close to the detection line, of the reaction film, the sample pad is overlapped with the other end of the conjugate pad, the absorbent paper is overlapped with one end, close to the quality control line, of the reaction film, and all overlapping distances are within a preset distance range; the test strip is fixed in the shell; the sample adding hole is formed above the sample pad; the observation window is arranged above the reaction film and is large enough to expose the detection line and the quality control line on the reaction film, so that the measurement sensitivity is improved.

The application provides a biomarker of renal cancer with venous cancer embolus and application thereof, and relates to the technical field of bioinformatics.The biomarker of renal cancer with venous cancer embolus comprises serum amyloid A.The biomarker can improve the treatment effect: by revealing the action mechanism of SAA in the treatment of renal cancer embolus, the application provides a basis for optimizing a neoadjuvant target immune combined treatment scheme, and improves the treatment effect.The biomarker can reduce treatment drug resistance: by regulating SAA and a related signal path, the application can enhance the sensitivity of tumor cells to target immune treatment, and reduce the occurrence of drug resistance.The biomarker has important clinical application value: the application provides a new biomarker and a treatment target for the clinical treatment of renal cancer embolus patients, and has important clinical application value.The detection of SAA can be used as an important index for evaluating treatment efficacy and predicting drug resistance, guiding clinical treatment decisions, and improving the treatment effect and life quality of patients.

The invention provides a biological marker for kidney cancer with vein cancer thrombus and application of the biological marker, and relates to the technical field of bioinformatics. The biological marker for the kidney cancer with the vein cancer thrombus comprises serum amyloid protein A. The biomarker disclosed by the invention can improve the treatment effect: by revealing the action mechanism of SAA in kidney cancer embolus treatment, a basis is provided for optimizing a new auxiliary target-immunization combined treatment scheme, and the treatment effect is improved. The biomarker provided by the invention can reduce treatment drug resistance: by regulating SAA and related signal channels thereof, the sensitivity of tumor cells to target immunotherapy can be possibly enhanced, and occurrence of drug resistance is reduced. The clinical application value of the biomarker is as follows: a new biomarker and a treatment target are provided for clinical treatment of patients with kidney cancer thrombus, and the biomarker has important clinical application value. The SAA detection can be used as an important index for evaluating the treatment effect and predicting the drug resistance, and is used for guiding clinical treatment decisions and improving the treatment effect and life quality of patients.

The application discloses a single-domain antibody of serum amyloid protein SAA, a nucleotide sequence coding the single-domain antibody is shown as SEQ ID NO:1, and an amino acid sequence of the single-domain antibody is shown as SEQ ID NO:2. The single-domain antibody of serum amyloid protein SAA provided by the application shows excellent stability in a range from normal temperature to 50 DEG C, especially can be stored for a long time under the condition of normal temperature to 50 DEG C, obviously reduces the difficulty of antibody storage, and effectively saves the cost of storage and transportation.